

ASX ANNOUNCEMENT

20 January 2010

VitroGro® Commercial Scale Manufacturing

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced today the successful negotiation of a manufacturing contract with Eurogentec SA of Belgium for the commercial scale, Good Manufacturing Practice (cGMP) production of VitroGro®.

The VitroGro® produced by Eurogentec will be used in the already announced human wound healing trial to be conducted by Professor Keith Harding of Cardiff University and for the world-wide sale of VitroGro® wound healing and cell culture products. (Please see **ASX: TIS Human Trial of VitroGro®: Prof. Keith Harding, Cardiff University, 7 January 2010.**)

The CEO of Tissue Therapies, Dr Steven Mercer said. "We are delighted to have Eurogentec perform the commercial scale production of VitroGro®. It was evident from our detailed selection process that the experience of the Eurogentec staff over more than 10 years with more than 400 GMP batches to produce more than 80 biopharmaceutical products provides them with world class experience in the processes necessary for the optimal production of VitroGro®."

"We were also impressed during negotiations on site in Belgium with the knowledge and expertise of the Eurogentec scientific staff and management team as well as the manufacturing facilities."

"Another important milestone in the commercialisation plan of VitroGro® is in place, on schedule."

Further information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute of Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic skin ulcers and burns.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com